Toggle light / dark theme

Liz mentions combinatorial gene therapy for aging near the end which is something you hear the likes of George Church mention they are working on.


Liz Parrish is the founder of @BioViva Science, a company dedicated to curing biological aging, a disease that is at the root cause of all other chronic diseases from heart disease to Alzheimer’s. Watch this video to understand how much more control we have over our lifespan and health!

💻Connect with BioViva here:
Website: https://bioviva-science.com/
YouTube channel: https://www.youtube.com/channel/UCaBq8hEExcUN6mtKMEuBvMQ
Instagram: https://www.instagram.com/biovivasciences/
Twitter: https://twitter.com/BioVivaScience.
Facebook: https://www.facebook.com/BiovivaSciences/

💻Connect with Liz Parrish here:
Instagram: https://www.instagram.com/lizlparrish/
Twitter: https://twitter.com/parrishliz?lang=en.

☕EAT MEAT. LIFT. REPEAT. mug merch: https://bit.ly/3GuFUXx.

The reluctance of many in the medical field to classify aging as a disease is causing significant roadblocks for those trying to find a solution.


Many people will swear to the life extending properties of coffee, be it saving them from keeling over from exhausting in the early hours of the morning or saving an annoying co-worker from the unbridled rage of someone who hasn’t yet acquired their caffeine fix. Yes, coffee is without a doubt one of the most powerful (and mostly metaphorical) lifesavers of the modern world. However, recent studies into the effects of drinking coffee on human lifespan have found that it might very well have a significant impact on health and longevity. A study of 170,000 people from the UK found that those who drank between two and four cups of coffee a day were 30% less likely to die from all causes compared to those who did not drink coffee at all.

Cells not replaced, but old cells that are still there are rejuvenated.


Dr David Sinclair explains the mechanism behind how to reprogramm the old cells rejuvenate to be young again. He also clarify the process is based on cell autonomous effect and does not involve or rely on any stem cells in this clip.

David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming.

Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and he has called for greater international attention to the social, economic and political and benefits of a world in which billions of people can live much longer and much healthier lives.

Dr David Sinclair is the co-founder of several biotechnology companies (Life Biosciences, Sirtris, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others.

Wojtek Tek.

Tenor.

Sean Brazell is feeling thoughtful.

A short but recently released cryonics piece from the BBC focused on Alcor, a foundation based in the state of Arizona here in the United States. It runs the largest cryonics patient storage facility on earth, alongside it’s in-house research labs. It also helps fund many external research efforts around the world, including the funding of R&D in university medical and engineering research programs, as well as at both private and public corporate research facilities.

Having multiple conditions that affect the heart are linked to a greater risk of dementia than having high genetic risk, according to a largescale new study.

Led by Oxford University and the University of Exeter, the study is among the largest ever to examine the link between several heart-related conditions and dementia, and one of the few to look at the complex issue of multiple health conditions.

Published in The Lancet Healthy Longevity, the paper looked at data from more than 200,000 people, aged 60 or above, and of European ancestry in UK Biobank. The international research team identified those who had been diagnosed with the cardiometabolic conditions diabetes, stroke, or a heart attack, or any combination of the three, and those who went on to develop dementia.

Osaka University researchers discovered that adjusting lifestyle behaviors can have a significant impact on lifespan, even in those with chronic health issues.

Ever since the beginning of civilization, humans have wanted to live longer. Whether it be the Fountain of Youth, Gilgamesh’s secret plant of immortality, or the elixir of life, the idea of immortality is incredibly prevalent in humanity’s oldest and most well-known stories.

Unfortunately, immortality is only a myth. The average lifespan in the United States is nearly 79 years and it is unlikely to increase dramatically in the next few years. Still, scientists have been researching how to increase our longevity and have found promising results.

New research has uncovered how genetic changes that accumulate slowly in blood stem cells throughout life are likely to be responsible for the dramatic change in blood production after the age of 70.

The study, by scientists at the Wellcome Sanger Institute, the Wellcome-MRC Cambridge Stem Cell Institute and collaborators, has been published in the journal Nature.

Longevity. Technology: Has our understanding of one of the mechanisms of aging taken a quantum leap? Molecular damage accumulates throughout our lives, gradually increasing year-on-year as we suffer telomere attrition, mutation, epigenetic change and oxidative and replicative stress. It’s a double whammy as our ability to repair this damage also declines as we age, but given the gradual nature of these processes, why, as the paper authors themselves put it, “Is there an abrupt increase in mortality after 70 years of age? [1].

As people across the globe look forward to longer life expectancies, malignant cancers continue to pose threats to human health. The exploration and development of immunotherapy aims to seek new breakthroughs for the treatment of solid tumors.

The successful establishment of anti-tumor immunity requires the activation, expansion and differentiation of antigen-specific lymphocytes. This process largely depends on specific interactions between various T cells and antigen-presenting cells (APCs) in the body. However, existing tumor vaccines, such as neoantigen vaccines and various vector vaccines, all rely on random interactions with APCs in the body. Furthermore, inappropriate interactions may lead to the silencing of other immune responses.

Although immune checkpoint-based immunotherapy has been shown to have great potential, only a small proportion of patients fully respond to this therapy, and the relevant molecular mechanisms need to be further explored. This delivery method is however complex and inefficient.